Gefitinib ('Iressa', ZD1839) for patients with advanced non-small-cell lung cancer treated in the 'Iressa' Expanded Access Programme at a single institution in Brazil

被引：0
|
作者：
Katz, A [1 ]
Smaletz, O [1 ]
Simon, SD [1 ]
Rene, GC [1 ]
Hoff, PM [1 ]
Tabacof, J [1 ]
机构：
[1] Hosp Israelita Albert Einstein, Ctr Paulista Oncol, Sao Paulo, Brazil
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [1] Gefitinib ('Iressa', ZD1839) given in the 'Iressa' Expanded Access Programme in patients with non-small-cell lung cancer
    Chioni, A
    Barbieri, F
    Baldini, E
    Orlandini, C
    Ricci, S
    Conte, PF
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S26 - S27
  • [2] Analysis of the efficacy and tolerability of gefitinib ('Iressa', ZD1839) in previously treated patients with non-small-cell lung cancer enrolled in the 'Iressa' Expanded Access Programme
    de Leeuw, K
    Schallier, D
    Sermijn, E
    Fontaine, C
    Neyns, B
    Samijn, I
    de Grève, J
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S28 - S28
  • [3] Gefitinib ('Iressa', ZD1839) in heavily pretreated non-small-cell lung cancer patients: a case series report from the 'Iressa' Expanded Access Programme
    Gridelli, C
    Rossi, A
    Maione, P
    Musto, L
    Del Gaizo, F
    Airoma, G
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S29 - S29
  • [4] Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study
    Dongiovanni, Vincenzo
    Dongiovanni, Diego
    Buffoni, Lucio
    Barone, Carla
    Fissore, Camilla
    Addeo, Alfredo
    Larovere, Erika
    Grillo, Raffaella
    Nuzzolo, Gloria
    Schena, Marina
    Bertetto, Oscar
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 21 - 22
  • [5] Gefitinib ('Iressa', ZD1839) in relapsed non-small-cell lung cancer
    Reck, M
    Gatzemeier, U
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S32 - S33
  • [6] Gefitinib ('Iressa', ZD1839) as treatment for non-small-cell lung cancer
    Razis, E
    Papadopoulos, S
    Skarlos, D
    Exarchakos, M
    Christodoulou, C
    Karina, M
    Xylouri, M
    Labropoulos, S
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S32 - S32
  • [7] Gefitinib ('Iressa', ZD1839) in advanced non-small-cell lung cancer patients progressed to chemotherapy
    Cortes-Funes, H
    Figueiras, MC
    Martín-Algarra, S
    Salinas, P
    Massutí, B
    Gascón, P
    Rosell, R
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S27 - S27
  • [8] Refractory non-small-cell lung cancer: clinical experience with gefitinib ('Iressa', ZD1839) in 28 patients who entered the 'Iressa' Expanded Access Programme at the Sydney Cancer Centre
    Boyer, M
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S26 - S26
  • [9] Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer
    Hotta, K
    Kiura, K
    Ueoka, H
    Tabata, M
    Fujiwara, K
    Kozuki, T
    Okada, T
    Hisamoto, A
    Tanimoto, M
    [J]. LUNG CANCER, 2004, 46 (02) : 255 - 261
  • [10] Outcomes of patients with advanced non-small cell tung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study
    Jänne, PA
    Gurubhagavatula, S
    Yeap, BY
    Lucca, J
    Ostler, P
    Skarin, AT
    Fidias, P
    Lynch, TJ
    Johnson, BE
    [J]. LUNG CANCER, 2004, 44 (02) : 221 - 230
12345